PharmaVOICE Blog Post

How does disruptive innovation drive positive outcomes?

Posted By: Dan Limbach
June 19, 2019

In the June Speak OUT feature in PharmaVOICE Magazine, Larissa Comis of Cognizant describes how the Cognizant Shared Investigator Platform is a disruptive innovation that can help companies achieve positive outcomes.

Best Practices for Adopting the Shared Investigator Platform

The Cognizant Shared Investigator Platform – SIP – is the disruptive innovation our industry sorely needs to reduce the burden placed on sites conducting clinical trials.

Stakeholders from across the industry have expressed that sentiment to me countless times since I joined Cognizant six months ago as the product lead for SIP.

The need for a technology platform that unifies all stakeholders is clearly demonstrated in the recent SIP adoption metrics:

  • More than 23,000 site users are now registered in SIP across 80 countries, and growing by thousands per month
  • Two more large pharmaceutical sponsors went live on SIP this year, bringing the total to six, with more in the queue for the second half of 2019
  • SIP is now officially available to all biopharmaceutical sponsors
  • Large academic research and site management organizations are committing to SIP, now that the platform allows them to easily manage their networks of investigators and sites

The speed and scale of change that disruptive innovations such as SIP brings to industry stakeholders is significant. Where SIP becomes integrated with other clinical systems such as CTMS and eTMF, organizational change management (OCM) is vital to drive the highest levels of efficiencies and timesavings possible. Important components of OCM include:

Communications Planning – a month-by-month plan to communicate to all impacted stakeholders, especially sites and site-facing staff

Stakeholder Engagement Plan – ensuring that the voice of all impacted stakeholders is incorporated into SIP implementation, through interviews and surveys

Readiness Assessment – developing a long-term assessment of sponsor users’ readiness for SIP; measuring over time to gauge comfort and comprehension

Change Impact Analysis – analyzing all business processes impacted by SIP, understanding the changes to roles and risks created and developing action plans to mitigate risks

Project Metrics – measuring sponsor user adoption, training effectiveness, communications effectiveness

Benefits Realization – stemming from the business case for implementing SIP, developing a long-term plan and measuring the business benefits of adopting SIP (e.g. time between study startup milestones, financial savings)

Training Planning & Delivery – developing a training needs analysis, curricula and training plan to ensure that all roles impacted by SIP receive customized training for the skills and functions needed, delivered at the right time

To learn more about successful adoption of the Shared Investigator Platform, meet the SIP team in Booth 2221, and join my presentation with Summer Iverson of Pfizer on Monday, June 24, at DIA 2019.

About the Blog Poster: Dan Limbach

Post a Comment

You must be logged in to post a Comment.

FEEDBACK